Identifying specific chemotherapeutic agents in Medicare data: a validation study - Wikidata - awgldk - TriplyDB

Identifying specific chemotherapeutic agents in Medicare data: a validation study

Identifying specific chemotherapeutic agents in Medicare data: a validation study

http://www.wikidata.org/entity/Q30413422

about

Comparison of SEER Treatment Data With Medicare Claims.Accuracy of using Diagnosis Procedure Combination administrative claims data for estimating the amount of opioid consumption among cancer patients in Japan.Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data.A Validation Study of Administrative Claims Data to Measure Ovarian Cancer Recurrence and Secondary Debulking Surgery.Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.Long term survival with thoracoscopic versus open lobectomy: propensity matched comparative analysis using SEER-Medicare database Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients.Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States.Trends in Anemia Management in Hemodialysis Patients with Cancer The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients.Patterns of Colorectal Cancer Care in the United States: 1990-2010.Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients.Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare, Medicaid, and privately insured women.Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer?Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program.Gynecologic oncologists involvement on ovarian cancer standard of care receipt and survival.Trends in Antineoplastic Receipt after Medicare Payment Reform: Implications for Future Oncology Payment Design

P2860

Q30779910-59CC3802-B746-4BAD-97CD-C710137A6188 Q30992942-260902FD-E02F-44C5-95C6-B1AFF72A460B Q31035145-BC545EB7-BF7A-4512-B6D9-15EB7E9E29D8 Q31144976-7241A78A-25AF-4CF7-B38C-E012B77D0A72 Q33846793-57AB083C-36EC-4763-A76E-3D8115625831 Q34055498-E39FD34E-C1AC-4D8A-BAD9-0BD5DFAB2E63 Q34280296-84D37668-CCFB-4E30-828D-9BFDD6CADB1C Q34978347-9DDB9A4A-2C8F-40EA-B6E5-AE830B865F66 Q35602510-41A600EB-B255-4CDF-81E0-5DC18666B678 Q35748060-CCE26BE8-07C3-42A0-872B-A197E7779AE0 Q36200205-6F6427B2-AE6F-4CFC-9716-54A30CBBB3B7 Q36280941-A94A4CB0-E37D-435C-BC0E-4FBCDE04FF55 Q36598736-46AEADA6-5BFC-4CF4-BD2A-A56FB611EBD2 Q36761488-0C50F922-AAD9-46F8-9730-8FC941C79E8D Q36824126-FC484DBD-0057-44A2-80EF-54F3E4D8A41E Q36852163-3DB6C081-ED1E-4A69-9A23-BC369AD9DD83 Q36869758-2F02D8F2-B5F1-44A9-892B-65AAFACA3F48 Q36913615-0861A8F1-2E54-4D5F-8913-3501CAA3C817 Q37164131-72B5FB4A-DE4B-4DA5-93E8-3971130BDC5C Q37365689-040A9D90-9E59-4C43-A34D-9B6F6664D5DD Q37627696-72AFE03F-B248-47DF-910F-03CBD5781DD0 Q37644543-F9E50E85-7097-44DA-B834-B93E628DFD10 Q38174422-321A42F4-8856-40A3-A1EC-89E0429A3ECB Q39532324-F89D45A9-7FA4-4734-B6A1-1A0DADA26551 Q39808566-678470B6-52EA-4291-9439-CB6EF4C2C840 Q43508505-2A74281A-A03A-4560-BED0-87E06E8DA322 Q44361470-AECEADDA-87B3-4F4A-9DF2-E03DFCF66C24 Q50075321-2CAC557D-7CF6-4895-A8C9-C2BDE3106FC4 Q55005151-284A69EA-7E36-463C-A3BA-D884AF7C3805 Q55137369-E694F947-8599-4BDB-97FF-1AC5A3352E0F Q57822900-61E4DA71-2F0F-43ED-B456-B3DED41C343A

P2860

Identifying specific chemotherapeutic agents in Medicare data: a validation study

http://www.wikidata.org/entity/Q30413422

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Identifying specific chemotherapeutic agents in Medicare data: a validation study

@ast

Identifying specific chemotherapeutic agents in Medicare data: a validation study

@en

type

label

Identifying specific chemotherapeutic agents in Medicare data: a validation study

@ast

Identifying specific chemotherapeutic agents in Medicare data: a validation study

@en

prefLabel

Identifying specific chemotherapeutic agents in Medicare data: a validation study

@ast

Identifying specific chemotherapeutic agents in Medicare data: a validation study

@en

P1433

Q30413422-D657E57C-0981-47EB-A640-4F84B3FB1684

P1476

Q30413422-11C4D319-993F-4F14-B287-F2C50E5DDF14

P2093

Q30413422-4065033A-522B-46DE-8034-E29759B366C2

Q30413422-4931143C-10A0-479C-A456-57F62EC61AEA

Q30413422-73017626-E1ED-4130-A0E9-41AAC86530D9

Q30413422-A5D0BC08-D1E6-4425-B6F7-237C22E95C5D

Q30413422-BDE0D32E-3E42-4FD2-8A17-F91A030A1A9C

P2860

Q30413422-033738BB-3A2C-47E2-A89B-71896B603F29

Q30413422-09F3BF67-31DE-4F3D-A96A-8DD5F82CB3F9

Q30413422-0E6844A8-855B-46B5-92F0-B2E5664CD57C

Q30413422-0FE0D8C3-D2C5-4297-B8C9-D88BBCA69B92

Q30413422-1146AEE0-1289-4A7D-8DC4-76D962E941EE

Q30413422-1EC21C36-0699-450D-B7F1-288CDAE712C5

Q30413422-24E9D585-BE31-4D92-BE36-C4AB0316BC92

Q30413422-286002CC-7D6F-4AF4-9DDF-D474DB879D6C

Q30413422-31F2852D-09E6-4AD4-B346-8E7787183F86

Q30413422-37BC8681-B265-40B4-B4DC-F4B083E06B91

P304

Q30413422-BC84EAA2-873B-48EF-81C0-3B983EF47FD7

P31

Q30413422-FAD05C15-4BE9-45B6-877A-8D5BFEDE19FA

P356

Q30413422-D2EE5207-C308-4EFA-8547-6FCD2E6708AE

P433

Q30413422-9619B229-5111-438F-B9D4-C6200A4764F0

P478

Q30413422-165782D8-26FB-42D2-ACBD-7431CBFF9EF5

P50

Q30413422-5391D994-22D3-4C79-A9A0-CE61E4CD9C94

Q30413422-F05DE882-7700-4B94-AB7A-F00325514EB4

P577

Q30413422-2E1B347A-07BB-4B41-8A89-FE2BE5C5A212

P698

Q30413422-554A21B6-0F21-49B1-852A-046368C7D717

P921

Q30413422-50870A69-4CA5-45BE-8F2B-1534D0A521C3

Q30413422-67E93802-44C2-48CE-90F6-70973D51AC12

P932

Q30413422-F4806890-7BA6-4906-B8FE-9E991CBC36F4

P356

MLR.0B013E31823AB60F

P1433

P1476

Identifying specific chemotherapeutic agents in Medicare data: a validation study

@en

P2093

Hanna K Sanoff

http://www.w3.org/2001/XMLSchema#string

Jennifer L Lund

http://www.w3.org/2001/XMLSchema#string

Joan L Warren

http://www.w3.org/2001/XMLSchema#string

Linda C Harlan

http://www.w3.org/2001/XMLSchema#string

Maurice Alan Brookhart

http://www.w3.org/2001/XMLSchema#string

P2860

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Utility of the SEER-Medicare data to identify chemotherapy use.

Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data.

Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer.

Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer.

Construct validity of medicare chemotherapy claims: the case of 5FU.

Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer.

Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population.

Completion of therapy by Medicare patients with stage III colon cancer.

Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.

P304

e27-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MLR.0B013E31823AB60F

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Robert S Sandler

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22080337

http://www.w3.org/2001/XMLSchema#string

P921

P932

3290707

http://www.w3.org/2001/XMLSchema#string